Neumora Therapeutics Inc NMRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
-
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations
-
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
Trading Information
- Previous Close Price
- $1.65
- Day Range
- $1.58–1.71
- 52-Week Range
- $0.83–3.65
- Bid/Ask
- $1.65 / $1.73
- Shares Outstanding
- 185.28M
- Market Cap
- $311.28M
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 92
- Website
- https://www.neumoratx.com
Valuation
|
Metric
|
NMRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.48 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NMRA
|
|---|---|
Quick Ratio | 4.88 |
Current Ratio | 5.09 |
Interest Coverage | — |
Quick Ratio
NMRA
Profitability
|
Metric
|
NMRA
|
|---|---|
Return on Assets (Normalized) | −99.82% |
Return on Equity (Normalized) | −139.50% |
Return on Invested Capital (Normalized) | −116.13% |
Return on Assets
NMRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#bhd^Bl | LOCK|ysZK> | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!&V^Ty | LOCK|^P#B | $70B | |||
| argenx SE ADR
ARGX
| LOCK|@dHJ@> | LOCK|@q | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|GBkBd<c | LOCK|jXG^n | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|KCt#Zj@ | LOCK|&@ | $36B | |||
| Moderna Inc
MRNA
| LOCK|Lw&wz@# | LOCK|l<H | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<Pj^>jGt | LOCK|Y<%W# | $25B | |||
| Incyte Corp
INCY
| LOCK|!!@$vk? | LOCK|>@n | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|?y$M$! | LOCK|Kf? | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Q&YRP@ | LOCK|<VB | $17B |
United States